Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Compass Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
CMPX
Nasdaq
2836
www.compasstherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Compass Therapeutics, Inc.
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist
- Jun 12th, 2025 6:05 am
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
- May 28th, 2025 6:00 am
Spotlight On Three Promising Penny Stocks In May 2025
- May 14th, 2025 12:08 pm
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
- May 8th, 2025 6:00 am
Compass Therapeutics to Participate in Upcoming May Investor Events
- May 6th, 2025 6:00 am
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
- Apr 28th, 2025 6:00 am
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
- Apr 21st, 2025 6:00 am
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
- Apr 2nd, 2025 2:05 pm
Compass Therapeutics And 2 More Compelling Penny Stocks
- Apr 2nd, 2025 5:05 am
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
- Apr 1st, 2025 5:00 am
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
- Mar 31st, 2025 2:05 pm
With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest
- Mar 18th, 2025 6:12 am
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025
- Mar 2nd, 2025 8:22 am
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
- Feb 27th, 2025 6:00 am
3 Penny Stocks On US Exchanges With Market Caps Under $500M
- Feb 5th, 2025 5:06 pm
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
- Jan 29th, 2025 6:00 am
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
- Jan 8th, 2025 6:00 am
US Penny Stocks To Watch In January 2025
- Jan 7th, 2025 10:08 am
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
- Dec 10th, 2024 6:00 am
Top US Penny Stocks To Watch In December 2024
- Dec 3rd, 2024 5:08 pm
Scroll